USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
In a filing with the US Securities and Exchange Commission (SEC), Californian biotech Alumis has revealed it aims to raise around $300 million in its upcoming initial public offering (IPO). 25 June 2024
Deal volume was up 20% in the pharmaceutical and life sciences sector in the last 12 months as dealmakers grew more comfortable with uncertainty, according to a report from PwC. 21 June 2024
California-based āshibio, a privately-held biotech developing therapeutics for bone and connective tissue disorders, has exited stealth mode today with $40 million in seed and Series A financing. 21 June 2024
Kotak Alt, part of India's Kotak Mahindra Group, has invested $173 million in Matrix Pharma to facilitate its acquisition of Viatris’ (Nasdaq: VTRS) active pharmaceutical ingredient (API) business, a major US-based company. 19 June 2024
Third Rock incubated clinical-stage biotech Marea Therapeutics launched yesterday with $190 million in combined Series A and B financings. 19 June 2024
The private biotech sector witnessed a 46% increase in total venture financing deal value in the first quarter of 2024 compared to the fourth quarter of 2023. 19 June 2024
Elion Therapeutics, a biotechnology company focusing on invasive fungal infections, has announced the successful closing of an $81 million series B funding round. 17 June 2024
Australian clinical-stage ophthalmic specialist Opthea Limited says it has successfully completed an institutional component of the capital raising. 15 June 2024
Avidity Biosciences, a biopharmaceutical company specializing in RNA therapeutics, has announced a public share offering, with the goal of raising $400 million. 14 June 2024
First launched in 2022, US precision immunology company Santa Ana Bio yesterday emerged from stealth with $168 million in combined Series A and B funding. 14 June 2024
Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners. 13 June 2024
Aardvark Therapeutics might not have scored the biggest venture haul in May, but its $85 million Series C round will further strengthen rumors that the California-based company is gearing up for an IPO this summer, which could come as soon as late July. 13 June 2024
Bright Peak Therapeutics yesterday announced that it raised $90 million in a Series C financing, as the privately-held biotech looks to make a name for itself in the immunoconjugate space. 12 June 2024
Biotechnology star-tup Alumis is set to go public, filing with the US Securities and Exchange Commission for an initial public offering (IPO). 11 June 2024
Isotope Technologies Munich (ITM) has announced an equity investment of 188 million euros ($204 million) led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne. 6 June 2024
Australian radiopharma developer Telix Pharmaceuticals has announced the launch of its initial public offering in the USA of 17,000,000 American Depositary Shares (ADSs), each representing one ordinary share in Telix. 6 June 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news